Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03212261 · ClinicalTrials.gov registry record · NA
Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT03212261: Completed NA study, sponsored by Massachusetts General Hospital.
NCT03212261 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03212261, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).
Interventions
- BEHAVIORAL 3RP-Lymphoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2018-09-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03212261
The ClinicalTrials.gov registry entry for NCT03212261 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3RP-Lymphoma is the first listed.
NCT03212261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03212261 about?
NCT03212261 is a clinical study titled "Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma". The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).
What is the current status of trial NCT03212261?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2017-08-03. Estimated completion is 2018-09-24.
What interventions are being tested in trial NCT03212261?
The interventions under investigation include: 3RP-Lymphoma (BEHAVIORAL).
Who is sponsoring clinical trial NCT03212261?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.